精品久久久久中文慕人妻,男女做暧暧禁止18免费,91天堂亚洲无码艹逼,乱伦3PaV片

Atectura? Breezhaler?
Atectura? Breezhaler?
Atectura? Breezhaler?

Generic Name of Medicine: Indacaterol Acetate and Mometasone Furoate Powder for Inhalation II, III

Applicable Symptoms: Atectura? Breezhaler? is an innovative combination of ICS mometasone furoate and LABA indacaterol acetate for the maintenance treatment of adult and 12 years old above adolescent patients with asthma. Atectura? Breezhaler? also has the characteristics including “visible and controllable, precise inhalation, once a day” etc. It can significantly improve the lung function of patients and reduce the risk of acute attacks, and is a new choice for optimal treatment of asthma patients. The phase III clinical study of the product shows that, compared with the conventional high dose Salmeterol-Fluticasone powder for inhalation, Atectura? Breezhaler? can significantly improve the risk of acute attack in patients, and the risk of severe, moderately severe and all acute attack categories is reduced by approximately 26%, 22% and 19% respectively. Both products were officially included in the category-B medicines management scope in China’s National Reimbursement Drug List for Basic Medical Insurance, Work-Related Injury Insurance and Maternity Insurance (2022 version) (《國家基本醫(yī)療保險、工傷保險和生育保險藥品目錄(2022 年版)》), and provide new treatment method for people receiving long

Related Products